RKF Jr emphasizes lifestyle over weight-loss drugs

Published 13/12/2024, 03:30 am
© Reuters.
LLY
-
NOVOb
-

Robert F. Kennedy Jr., nominated by President-elect Donald Trump to lead the Department of Health and Human Services, shared his views on the burgeoning sector of weight-loss medications Thursday. Speaking with CNBC's Jim Cramer at the New York Stock Exchange, Kennedy emphasized the importance of healthy living as a primary approach to weight management.

Kennedy, known for his critical perspective on the pharmaceutical industry, underscored that lifestyle changes should be the initial response to obesity rather than immediately turning to GLP-1 drugs. His comments come at a time when Wall Street is closely monitoring his potential impact on health policy, following his nomination by Trump last month.

GLP-1 medications, including Novo Nordisk’s Wegovy and Ozempic, as well as Eli Lilly’s Zepbound and Mounjaro, have seen a surge in popularity, sparking a competitive race among pharmaceutical companies. The investor community has been particularly bullish on Novo and Eli Lilly (NYSE:LLY), with the latter becoming the world's most valuable health-care company. Forecasts suggest that the market for these drugs could reach or exceed $100 billion by 2030.

Kennedy's confirmation by the Senate is pending, and his position on GLP-1 drugs has been a focal point for investors trying to anticipate future health policies. His presence at the New York Stock Exchange, alongside other cabinet nominees, was part of the ceremonial opening bell event led by Trump on Thursday, marking the beginning of the trading session.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.